Korean J Intern Med.  2007 Mar;22(1):63-66. 10.3904/kjim.2007.22.1.63.

Adenoviral Pneumonia During Etanercept Treatment in a Patient with Rheumatoid Arthritis

• Kang MJ
• Kim MS
• Choi EH
• Lee KE
• Kim YK
• Choi HJ

• KMID: 1717999
• DOI: http://doi.org/10.3904/kjim.2007.22.1.63

Abstract

Inhibitors of tumor necrosis factor-alpha (TNF-alpha) have been approved for treating rheumatoid arthritis. As one of the biological response modifiers, etanercept has also been used in the treatment of psoriatic arthritis and inflammatory bowel disease. While etanercept is effective, certain infectious complications, such as tuberculosis, fungus, and cytomegalovirus, have been reported. We report the first Korean case of adenoviral pneumonia in a 55-year-old female who developed disseminated adenoviral infection following etanercept treatment, which resolved after anti-TNF-alpha discontinuation.

Keyword

Tumor Necrosis Factor-alpha; Pneumonia; Adenovirus Infections; Human; TNFR-Fc fusion protein

MeSH Terms

Risk Factors
Recombinant Fusion Proteins/immunology
Receptors, Tumor Necrosis Factor/immunology
Middle Aged
Immunoglobulin G/*adverse effects/immunology
Immunocompromised Host/drug effects
Humans
Female
Arthritis, Rheumatoid/*drug therapy
Antirheumatic Agents/*adverse effects/immunology
Antibodies, Monoclonal/*adverse effects/immunology
Adenovirus Infections, Human/*etiology/immunology